91 – 100 of 100
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
- Contribution to journal › Article
-
Mark
Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention
- Contribution to journal › Article
-
Mark
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
- Contribution to journal › Article
- 2008
-
Mark
Sex and muscle structural lipids in obese subjects - an impact on insulin action?
- Contribution to journal › Article
-
Mark
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
- Contribution to journal › Article
-
Mark
Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus
- Contribution to journal › Article
-
Mark
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
- Contribution to journal › Article
- 2007
-
Mark
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
- Contribution to journal › Article
-
Mark
Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?
- Contribution to journal › Article
-
Mark
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
- Contribution to journal › Article